Promises and challenges of personalized medicine to guide ARDS therapy

Identifying new effective treatments for the acute respiratory distress syndrome (ARDS), including COVID-19 ARDS, remains a challenge. The field of ARDS investigation is moving increasingly toward innovative approaches such as the personalization of therapy to biological and clinical sub-phenotypes. Additionally, there is growing recognition of the importance of the global context to identify effective ARDS treatments. This review highlights emerging opportunities and continued challenges for personalizing therapy for ARDS, from identifying treatable traits to innovative clinical trial design and recognition of patient-level factors as the field of critical care investigation moves forward into the twenty-first century.

Abstract licence: CC BY-NC-ND

1. 46.

   Hydrocortisone treatment in early sepsis-associated acute respiratory distress syndrome: results of a randomized controlled trial · 2016

2. 74.

   Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications · 2020

3. 93.

   Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial · 2021

4. 105.

   Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial · 2021

102 more references, whose wording the paper’s licence keeps private.

• Uridine Alleviates Sepsis-Induced Acute Lung Injury by Inhibiting Ferroptosis of Macrophage · 2023

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.